Compact Quadruple Therapy with the Lamivudine/Zidovudine Combination Tablet Plus Abacavir and Efavirenz, Followed by the Lamivudine/Zidovudine/Abacavir Triple Nucleoside Tablet Plus Efavirenz in Treatment-Naïve HIV-Infected Adults

REFERENCES

• Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-in-fected adults and adolescents. February 4,2002. Web site: http://www.hivatis.org/trtgdIns.html. Last accessed Febru-ary 20,2002.
   Google Scholar
• Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naIve HIV-1 infected adults. AIDS. 200115: 1369–1377.
   Google Scholar
• Jordan J, Carranza Rosenzweig J, Pathak D, PiIon T. Per-ceived influence of regimen characteristics on adherence. In: Programs and abstracts from the Fifth International Congress on Drug Therapy in HIV Infection; October 22–26, 2000; Glasgow, United Kingdom. Poster 121.
   Google Scholar
• Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch In-tern Med. 2001161:1962–1968.
   Google Scholar
• Geletko SM, ZuWallack AR. Treatment of hyperlipidemia in HIV-infected patients. Am J Health-System Pharm. 2001;58:607–614.
   PubMed Web of Science ®Google Scholar
• Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Reader. 2000;10:162–170.
   PubMedGoogle Scholar
• Brook MG, Dale A, Tomlinson D, Waterworth C, Daniels D, Forster G. Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units. AIDS Patient Care & STDs. 200115: 491–494.
   Google Scholar
• Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 200115: 2109–2117.
   Google Scholar
• Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 200115: 2441–2444.
   Google Scholar
• Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546–551.
   PubMedGoogle Scholar
• Martinez E, Garcia-Viejo MA, Blanch J, Gate!! JM. Lipodys-trophy syndrome in patients with HIV infection - quality of life issues. Drug Safety. 200124: 157–166.
   Google Scholar
• Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspec-tives on HIV-associated lipodystrophy syndrome: an up-date. AIDS. 2001;15:1917–1930.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001285: 1155–1163.
   Google Scholar
• Matheron S, Brun-Vezinet F, Katlama C, et al. 48-week results of the CNAF 3007/Ecureuil open label study: effi-cacy and safety of the triple nucleoside combination Combivir/abacavir versus Combivir/nelfinavir as first line antiretroviral therapy in HIV-1 infected adults. In: Program and abstracts from the Fifth International Congress on Drug Therapy in HIV Infection; October 22–26, 2000; Glasgow, United Kingdom. Abstract/poster 121.
   Google Scholar
• Vibhagool A, on behalf of the CNA3014 International Study Team. Abacavir/CombivirTm (ABC/COM) is comparable to indinavir/CombivirTm (IDV/COM) in HIV-1-infected antiretroviral therapy naive adults: results of a 48-week open-label study (CNA3014). In: Program and abstracts from the First International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; July 8–11, 2001; Buenos Aires, Argentina. Abstract/poster 063.
   Google Scholar
• Kumar P, Rodriguez-French A, Thompson M, et al. Pro-spective study of hyperlipidemia in ART-naïve subjects taking abacavir/Combivir (ABC/COM), COM/nelfinavir (NFV), or lamivudine (3TC)/stavudine (d4T)/NFV (GSK Pro-tocol E5540002). In: Program and abstracts from the Ninth Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 33.
   Google Scholar
• de Truchis P, Force G, Welker Y, et al. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. J Acquir Immune Defic Syndr. 2002;31:178–182.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41(no. RR–17).
   Google Scholar
• Yerly S, Rutschmann OT, Opravil M, et al. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. J Infect Dis. 1999;180:850–853.
   PubMed Web of Science ®Google Scholar
• Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lan-cet. 2000;355:1875–1881.
   PubMed Web of Science ®Google Scholar
• Childress JK, Jhingran P, Scott-Lennox J, Tolson J. Devel-opment and initial evaluation of the Patient Medication Adherence Questionnaire (PMAQ). In: Program and ab-stracts from the Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; October 11–15, 1997; Hamburg, Germany. Abstract N–23.
   Google Scholar
• Table for Grading of Adult Adverse Experiences. Washing-ton, DC: National Institute of Allergy and Infectious Dis-eases, Division of AIDS; August 1992.
   Google Scholar
• Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse tran-scriptase inhibitor abacavir. Clin Ther. 2001;23:1603–1614.
   PubMed Web of Science ®Google Scholar
• Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619–1624.
   PubMed Web of Science ®Google Scholar
• Jordan J, Cahn P, Vibhagool A, and the CNA3014 Study Team. Predictors of adherence and efficacy in HIV-1 in-fected patients treated with abacavir plus Combivir or indinavir plus Combivir: final 48-week data from CNA3014. In: Program and abstracts from the Ninth Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Poster 543T.
   Google Scholar
• Fischl M, Ribaudo H, Collier AC, et al. A randomized trial comparing 2 4-drug antiretroviral regimens with a 3-drug regimen in advanced HIV disease. In: Program and ab-stracts from the Ninth Conference on Retroviruses and Op-portunistic Infections; February 24–28, 2002; Seattle, Wash-ington. Abstract 41.
   Google Scholar
• Gulick RM, Smeaton LM, D'Aquila RT, et al. Indinavir, nevirapine, stavudine, and lamivudine for human immuno-deficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis. 2001183: 715–721.
   Google Scholar
• Fletcher CV, Acosta EP, Cheng HL, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 2000;14:2495–2501.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359. J Infect Dis. 2000;182:1375–1384.
   PubMed Web of Science ®Google Scholar
• Steffens CM, Smith KY, Landry A, et al. T cell receptor circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals. AIDS. 200115:1757–1764.
   Google Scholar
• Adkins JC, Noble S. Efavirenz. Drugs. 1998;56:1055–1064.
   PubMed Web of Science ®Google Scholar
• Moyle G. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs. 200161: 19–26.
   Google Scholar
• Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic out-comes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.
   PubMed Web of Science ®Google Scholar
• Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. In: Program and abstracts from the Sixth Conference on Retroviruses and Opportunistic Infections; January 31-Feb-ruary 4, 1999. Abstract 98.
   Google Scholar
• Laine C, Newschaffer CJ, Zhang D, Cosier L, Hauck WW, Turner BJ. Adherence to pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167–173.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• De Truchis P, Force G, Chemlal K, et al. An open-label study to evaluate safety and efficacy of switch to Trizivir (TZV) maintenance treatment after first-line quadruple in-duction therapy: AZLF3002 — Suburbs. In: Program and abstracts of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 28–31, 2001; Athens, Greece. Poster 76.
   Google Scholar